Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Interleukin-6 Receptor Inhibition for Avoiding Recurrence of Ischemic Stroke in Patients With Symptomatic Intracranial Atherosclerosis: a Double-blind, Randomized, Placebo-controlled Trial

NCT06447701 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT06447701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06447701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Interleukin-6 Receptor Inhibition for Avoiding Recurrence of Ischemic Stroke in Patients With Symptomatic Intracranial Atherosclerosis: a Double-blind, Randomized, Placebo-controlled Trial
Lead sponsor
Zhujiang Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 30, 2025
Completion date
June 30, 2029
Enrollment
486 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atheroscleroses, intracranial, atherosclerosis of artery, brain diseases, cerebral infarction, ischemia, ischemic stroke, stroke